IMPROVED CORONAVIRUS VACCINE
    505.
    发明公开

    公开(公告)号:US20240016917A1

    公开(公告)日:2024-01-18

    申请号:US18005573

    申请日:2022-04-12

    CPC classification number: A61K39/215 A61P31/04 A61K2039/55505

    Abstract: The present disclosure provides a glycoengineered SARS-CoV-2 spike protein which is capable of eliciting an enhanced immune response relative to a native spike protein of SARS-CoV-2 and its variants. The glycoengineered spike protein exposes the glycosylation sites and at the same time preserves the tertiary structure of the spike protein. The present disclosure therefore provides improved immunogens, vaccines, and methods for better prevention and treatment of the emerging coronavirus infections.

    Liposomes and uses thereof
    510.
    发明授权

    公开(公告)号:US11771651B2

    公开(公告)日:2023-10-03

    申请号:US17586807

    申请日:2022-01-28

    CPC classification number: A61K9/1271 A61K47/65 A61K47/6911

    Abstract: Disclosed herein are novel synthetic polypeptides and uses thereof in the preparation of liposomes. According to embodiments of the present disclosure, the synthetic polypeptide comprises a membrane lytic motif, a masking motif, and a linker configured to link the membrane lytic motif and the masking motif. The linker is cleavable by a stimulus, such as, light, protease, or phosphatase. Once being coupled to a liposome, the exposure to the stimulus cleaves the linker that results in the separation of the masking motif from the membrane lytic motif, which in turn exerts membrane lytic activity on the liposome that leads to the collapse of the intact structure of the liposome, and releases the agent encapsulated in the liposome to the target site. Also disclosed herein are methods of diagnosing or treating a disease in a subject by use of the present liposomes.

Patent Agency Ranking